}

Clopidogrel

Blood Thinners

Drug Overview

Clopidogrel, marketed under the brand name Plavix, is an oral antiplatelet medication.

It is used to reduce the risk of myocardial infarction, stroke, and other atherothrombotic events in patients with acute coronary syndrome, recent stenting, or a history of vascular disease.

Clopidogrel is a prodrug that is converted by liver enzymes—primarily CYP2C19—into an active metabolite that irreversibly inhibits the P2Y12 receptor on platelets, preventing aggregation and clot formation.

Relevant Genes and Their Roles

The key gene involved in clopidogrel activation is CYP2C19, which encodes an enzyme responsible for metabolizing the prodrug into its active form. Metabolism refers to the chemical process by which the body converts medications into active or inactive compounds.

Genetic variants in CYP2C19 can increase, decrease, or eliminate enzyme function. For example, the *17 allele boosts activity, while the *2 and *3 alleles reduce it. These changes can alter how much active drug is available to exert its antiplatelet effect.

Impact of Genetics on Drug Response

Patients are categorized into CYP2C19 metabolizer phenotypes—ultrarapid, rapid, normal, intermediate, and poor—based on their genotype. Ultrarapid and rapid metabolizers generate normal or higher levels of active metabolite and achieve expected platelet inhibition with standard dosing. Intermediate and poor metabolizers produce less active drug, leading to reduced antiplatelet effect and an increased risk of recurrent cardiovascular events.

Expected Clinical Effects of Genetic Variation

Ultrarapid Metabolizers

  • Effect on drug levels: Increased conversion to active metabolite
  • Clinical consequence: Standard antiplatelet effect
  • Side effects: No increased bleeding risk reported

Rapid Metabolizers

  • Effect on drug levels: Slightly increased conversion to active metabolite
  • Clinical consequence: Normal platelet inhibition
  • Side effects: No increased bleeding risk reported

Normal Metabolizers

  • Effect on drug levels: Normal active metabolite formation
  • Clinical consequence: Standard antiplatelet efficacy
  • Side effects: Typical bleeding risk (~1–2% major bleeding)

Intermediate Metabolizers

  • Effect on drug levels: Reduced active metabolite formation
  • Clinical consequence: Diminished antiplatelet effect; higher risk of cardiovascular events
  • Side effects: Bleeding risk similar to normal, but efficacy reduced

Poor Metabolizers

  • Effect on drug levels: Markedly reduced active metabolite formation
  • Clinical consequence: Significantly lower antiplatelet effect; increased risk of stent thrombosis and recurrent MI
  • Side effects: Bleeding risk not increased, but efficacy very low

Indeterminate/Not Available

  • Effect: Unknown
  • Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring
  • Side effects: Unknown

Dosing Guidelines

The following dosing guidelines are based on the available guidelines for CYP2C19 genotype-guided clopidogrel therapy.

CYP2C19 Dosing Guideline

Phenotype Clinical Consequence Guideline Recommendation
Ultrarapid Metabolizer Increased active metabolite; lower on-treatment platelet reactivity; no increased bleeding risk Use standard dose clopidogrel (75 mg/day)
Rapid Metabolizer Normal or increased active metabolite; normal or lower on-treatment platelet reactivity; no increased bleeding risk Use standard dose clopidogrel (75 mg/day)
Normal Metabolizer Normal active metabolite formation; normal platelet reactivity Use standard dose clopidogrel (75 mg/day)
Likely Intermediate Metabolizer Reduced active metabolite; increased platelet reactivity; higher cardiovascular risk Avoid clopidogrel 75 mg; use prasugrel or ticagrelor at standard dose if no contraindication
Intermediate Metabolizer Reduced active metabolite; increased platelet reactivity; higher cardiovascular risk Avoid clopidogrel 75 mg; use prasugrel or ticagrelor at standard dose if no contraindication
Likely Poor Metabolizer Significantly reduced active metabolite; increased platelet reactivity; higher cardiovascular risk Avoid clopidogrel; use prasugrel or ticagrelor at standard dose if no contraindication
Poor Metabolizer Significantly reduced active metabolite; increased platelet reactivity; higher cardiovascular risk Avoid clopidogrel; use prasugrel or ticagrelor at standard dose if no contraindication
Indeterminate No CPIC guidance Initiate therapy with recommended starting dose
Not available No CPIC guidance Initiate therapy with recommended starting dose

Alternative Treatment Options

These examples from guidelines are provided for context and are not medical advice:

  • Prasugrel (Effient)
  • Ticagrelor (Brilinta)

Sources and References

Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested